Department of Interventional Radiology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
Department of Interventional Radiology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
J Vasc Surg Venous Lymphat Disord. 2024 Mar;12(2):101698. doi: 10.1016/j.jvsv.2023.101698. Epub 2023 Oct 27.
The objective of this study was to retrospectively evaluate the effectiveness of polidocanol in managing pain, swelling, functional limiting and cosmetic disorders in patients with venous malformations (VMs).
This retrospective study included patients who underwent sclerotherapy with polidocanol for VMs between 2020 and 2022. Patient records, imaging findings, and evaluation questionnaires used in the preprocedure and follow-up phases were reviewed. After sclerotherapy, patients were followed up at 1, 2, 3, and 6 months. During these visits, the previously used 11-point verbal numerical rating scale (from 0 [no pain] to 10 [worst pain thinkable]) was used to evaluate the severity of symptoms such as pain, swelling, cosmetic discomfort, and functional limitation, and patients were asked to report the number of days per week they experienced these symptoms owing to the VM.
A total of 194 sclerotherapy procedures (mean, 1.6 ± 0.3 procedures) in 84 patients (55 female and 29 male patients; mean age, 22.45 ± 11.83 years) were conducted. The majority of these malformations (81%, or 68 patients) were located in the extremities. We found a significant decrease in pain, swelling, functional limitation, cosmetic appearance, and number of painful days between all time points, except for the comparison between months 3 and 6 (P < .001) CONCLUSIONS: Polidocanol sclerotherapy is a safe and effective treatment for VMs that significantly decreases patient complaints and has a very low complication rate. Particularly, following patients at short intervals and administering additional sclerotherapy sessions when necessary will significantly increase patient satisfaction.
本研究旨在回顾性评估聚多卡醇治疗静脉畸形（VM）患者疼痛、肿胀、功能受限和美容障碍的效果。
本回顾性研究纳入了 2020 年至 2022 年期间接受聚多卡醇硬化治疗的 VM 患者。回顾了患者病历、影像学检查结果和治疗前及随访阶段使用的评估问卷。硬化治疗后，患者在 1、2、3 和 6 个月时进行随访。在这些就诊期间，使用之前的 11 点数字评分法（从 0[无痛]到 10[可想象的最痛]）评估疼痛、肿胀、美容不适和功能受限等症状的严重程度，并询问患者每周因 VM 出现这些症状的天数。
共对 84 例患者（55 例女性和 29 例男性；平均年龄 22.45±11.83 岁）的 194 次硬化治疗（平均 1.6±0.3 次）进行了评估。这些畸形中的大多数（81%，68 例）位于四肢。我们发现所有时间点的疼痛、肿胀、功能受限、美容外观和疼痛天数均显著减少，除了 3 个月和 6 个月之间的比较（P<0.001）。
聚多卡醇硬化治疗是一种安全有效的 VM 治疗方法，可显著减轻患者的抱怨，且并发症发生率极低。特别地，密切随访患者并在必要时给予额外的硬化治疗，将显著提高患者的满意度。
